Our primary targets:

Bend Biomedical has four disease targets for mass drug administration: lymphatic filariasis, onchocerciasis, soil transmitted helminths (ascariasis, trichuriasis, and ancylostomiasis), and under-five mortality (sub-Saharan Africa only). Worldwide, over one billion people are afflicted by one or more of these diseases in the regions of Africa, Central America, South America, the Middle East, South Asia, and Southeast Asia. Our medicines also treat or prevent other diseases (extended targets1) including tropical pulmonary eosinophilia, scabies, strongyloidiasis, mansonelliasis, malaria transmission, oesophagostomiasis, trachoma, and yaws.

Our extended targets:

1PJ Hotez, Fenwick A, Molyneux DH. Collateral Benefits of Preventive Chemotherapy—Expanding the War on Neglected Tropical Diseases. N Engl J Med. 2019 June; 380(25):2389–91.